Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

A time for restraint.

Young FE.

Science. 2000 Feb 25;287(5457):1424.

PMID:
10688779
2.

A global health disaster network is needed.

Ferguson EW, Villasenor A, Cunnion S, de Ville de Goyet C, Young FE, Laporte RE.

BMJ. 1995 May 27;310(6991):1412. No abstract available.

3.

The economic impact of therapy on cancer patients.

Murphy GP, Prestifilippo J, Antman K, Berkman BJ, Huber SL, Kaufman D, Knox WA Jr, Lawrence W Jr, Levine RJ, Young FE.

Cancer. 1993 Nov 1;72(9 Suppl):2862-4. No abstract available.

PMID:
8402521
4.
5.

The impact of clinical trial protocols on patient care systems.

Lawrence W Jr, Antman K, Freeman HP, Huber SL, Kaufman D, Lantos J, Lenhard RE Jr, Levine RJ, McKenna RJ Sr, Young FE.

Cancer. 1993 Nov 1;72(9 Suppl):2839-41. No abstract available.

PMID:
8402515
6.

Efficacy of new tests and the safety of the blood supply.

Young FE.

Transfusion. 1990 Jan;30(1):4-5. No abstract available.

PMID:
2296789
7.

Aerosolized pentamidine. Approved for HIV-infected individuals at high risk for Pneumocystis carinii pneumonia.

Young FE, Nightingale SL, Cooper EC, Trapnell CB.

Arch Intern Med. 1989 Nov;149(11):2412-3.

PMID:
2818104
8.

The AIDS epidemic and clinical trials.

Young FE.

Acad Med. 1989 Nov;64(11):660-1. No abstract available.

PMID:
2803424
9.

Confronting the challenges with women at risk for osteoporosis.

Young FE.

Public Health Rep. 1989 Sep;104(Suppl):10. No abstract available.

10.
11.

Public statement on advancing biomedical technology.

Young FE.

J Parenter Sci Technol. 1989 Jul-Aug;43(4):194-6. No abstract available.

PMID:
2769529
12.

Newly approved treatment INDs.

Young FE.

Am Pharm. 1989 May;NS29(5):29-30. No abstract available.

PMID:
2729090
13.

AIDS research come to patients' home towns.

Young FE.

FDA Consum. 1989 May;23(4):6-7. No abstract available.

PMID:
10313019
14.
15.

'Deliberate releases' in Europe: over-regulation may be the biggest threat of all.

Young FE, Miller HI.

Gene. 1989 Jan 30;75(1):1-2. No abstract available.

PMID:
2721963
16.

Speeding help and hope to the desperately ill.

Young FE.

FDA Consum. 1989 Feb;23(1):8-9. No abstract available.

PMID:
10312854
17.

The FDA's regulation of biotechnology: an activist approach.

Miller HI, Young FE.

Bioessays. 1988 Nov;9(5):178-9. No abstract available.

PMID:
3240311
18.

Contemporary issues: diseases with a food vector.

Archer DL, Young FE.

Clin Microbiol Rev. 1988 Oct;1(4):377-98. Review.

19.

Information on treatment INDs as they become available to the practitioner.

Young FE, Nightingale SL.

JAMA. 1988 Jul 8;260(2):247. No abstract available.

PMID:
3385899
20.

FDA's newly designated treatment INDs.

Young FE, Nightingale SL.

JAMA. 1988 Jul 8;260(2):224-5. No abstract available. Erratum in: JAMA 1988 Nov 4;260(17):2510.

PMID:
2838651
22.

The role of the FDA in the effort against AIDS.

Young FE.

Public Health Rep. 1988 May-Jun;103(3):242-5.

23.

The FDA's new procedures for the use of investigational drugs in treatment.

Young FE, Norris JA, Levitt JA, Nightingale SL.

JAMA. 1988 Apr 15;259(15):2267-70.

PMID:
3280842
25.

Planned introductions of engineered organisms: wisdom from the U.S. National Academy of Sciences.

Miller HI, Young FE.

Bioessays. 1988 Apr;8(4):99-100. No abstract available.

PMID:
3163918
26.

The care and feeding of new biotechnology.

Young FE.

Gene. 1988;62(1):1-5. No abstract available.

PMID:
3371660
27.

Clinical evaluation of medicines used by the elderly.

Young FE.

Clin Pharmacol Ther. 1987 Dec;42(6):666-9. No abstract available.

PMID:
3690944
28.

Recombinant DNA release: European regulation.

Young FE, Miller HI.

Science. 1987 Nov 20;238(4830):1025. No abstract available.

PMID:
3685962
29.

DNA probes. Fruits of the new biotechnology.

Young FE.

JAMA. 1987 Nov 6;258(17):2404-6.

PMID:
3118062
30.

Risk assessment: the convergence of science and the law.

Young FE.

Regul Toxicol Pharmacol. 1987 Jun;7(2):179-84. No abstract available.

PMID:
3615957
31.

Proving Planck wrong. A perspective on the new biotechnology.

Miller HI, Young FE.

JAMA. 1987 May 1;257(17):2334. No abstract available.

PMID:
3573235
32.

Importance of WHO and the World Health Assembly to U.S. Public Health and Medicine: a Food and Drug Administration perspective.

Nightingale SL, Petricciani JC, Young FE.

Public Health Rep. 1987 May-Jun;102(3):260-3. No abstract available.

33.

Validation of medical software: present policy of the Food and Drug Administration.

Young FE.

Ann Intern Med. 1987 Apr;106(4):628-9. No abstract available.

PMID:
3826963
34.

Biotechnology: the view from the FDA.

Young FE.

Health Matrix. 1986 Fall;4(3):10-5.

PMID:
10279339
35.

Hazards of genetic engineering.

Young FE, Miller HI.

Nature. 1987 Mar 26-Apr 1;326(6111):326. No abstract available.

PMID:
3470602
36.

Recombinant DNA: International Guidelines.

Miller HI, Young FE.

Science. 1987 Jan 2;235(4784):14a. No abstract available.

PMID:
17769287
37.

Recombinant DNA: international guidelines.

Miller HI, Young FE.

Science. 1987 Jan 2;235(4784):14. No abstract available.

PMID:
3798092
38.

Evidence for prokaryotic transcription and translation control regions in the human factor IX gene.

Simpson PJ, Chou WG, Whitbeck AA, Young FE, Zain S.

Gene. 1987;61(3):373-83.

PMID:
2965665
39.

Biotechnology regulation.

Miller HI, Young FE.

Science. 1986 Sep 12;233(4769):1135-6. No abstract available.

PMID:
3461563
40.

Marketing approval for the lithotripter.

Nightingale SL, Young FE.

Isr J Med Sci. 1986 Jul-Aug;22(7-8):519-23.

PMID:
3781809
41.

Health technology assessment. The current political framework: the U.S. perspective.

Young FE.

Isr J Med Sci. 1986 Mar-Apr;22(3-4):173-8. No abstract available.

PMID:
3744767
42.

Autoplaquing in Neisseria gonorrhoeae.

Campbell LA, Short HB, Young FE, Clark VL.

J Bacteriol. 1985 Oct;164(1):461-5.

43.

Demystifying the FDA: Commissioner Young punches some holes in the "black box'. Interview by Don L. Gibbons.

Young FE.

Med World News. 1985 May 13;26(9):78-9, 83-4, 89-90 passim. No abstract available.

PMID:
10271160
44.
45.

More precise localization of the human factor IX gene by in situ hybridization.

Quirk S, Chou WG, Polakowska R, Zain SB, Young FE, Doherty RA.

Cytogenet Cell Genet. 1985;39(2):121-4.

PMID:
3839179
47.
48.

Characterization of Bacillus subtilis DSM704 and its production of 1-deoxynojirimycin.

Stein DC, Kopec LK, Yasbin RE, Young FE.

Appl Environ Microbiol. 1984 Aug;48(2):280-4.

49.

The effect of carbohydrate depletion on procoagulant activity and in vivo survival of highly purified human factor VIII.

Fay PJ, Chavin SI, Malone JE, Schroeder D, Young FE, Marder VJ.

Biochim Biophys Acta. 1984 Jul 30;800(2):152-8.

PMID:
6430352
50.

Cloning and mapping of the dihydrofolate reductase gene of Bacillus subtilis.

Myoda TT, Lowther SV, Funanage VL, Young FE.

Gene. 1984 Jul-Aug;29(1-2):135-43.

PMID:
6436144

Supplemental Content

Loading ...
Support Center